Introduction
Since the introduction of the first non-vitamin K antagonist oral anticoagulant (NOAC), i.e. rivaroxaban in 2012, the treatment patterns for venous thromboembolism (VTE) have changed. 1 With the advantages associated with the NOACs (no blood monitoring, limited drug-drug interactions, and fixed dose regimens), these agents have become the preferred choice of treatment. [1] [2] [3] [4] [5] In Denmark use of rivaroxaban has exceed that of vitamin K antagonists (VKA), with apixaban following a similar pattern of increasing use. 1 By September 2016, 12% initiated VKA, 70% initiated rivaroxaban, 16% initiated apixaban, and 2% initiated dabigatran. 1 Noteworthy, patients receiving apixaban are ORIGINAL ARTICLE often older than patients receiving rivaroxaban. 1 Rivaroxaban and apixaban are preferred over dabigatran and edoxaban, since both dabigatran and edoxaban require initial treatment with heparin. Bridging from heparin treatment to dabigatran or edoxaban treatment may be complex, resulting in only 2% of VTE patients initiate dabigatran per year in Demark and even less initiate edoxaban. 1, 6 The safety and efficacy of rivaroxaban and apixaban were established through large randomized trials, including more than 27 000 patients with acute VTE. [7] [8] [9] The most recent European Society of Cardiology (ESC) and CHEST guidelines do not differentiate between the individual NOACs, and it is up to the treating physician to choose between the NOACs. 10, 11 Meta-analyses have suggested that apixaban may be associated with a decreased risk of bleeding compared with rivaroxaban. 12, 13 The clinical trials [EINSTEIN (Oral rivaroxaban for symptomatic venous thromboembolism and oral rivaroxaban for symptomatic pulmonary embolism) and AMPLIFY (Oral apixaban for the treatment of acute venous thromboembolism)] that established the safety and efficacy of rivaroxaban and apixaban were heterogeneous. [7] [8] [9] Although the studies shared many similarities, the studies differed with regard to study design and patient inclusion and exclusion criteria, making it difficult to compare the results of the studies. 14, 15 The aim of our study was therefore to investigate the risk of all-cause mortality, recurrent VTE, and hospitalized bleeding in patients with VTE treated with either rivaroxaban or apixaban in a Danish nationwide cohort.
Methods

Data sources
The Danish Healthcare system is funded through taxes, which enables the Danish Government to provide free health care for all Danish residents. At birth or immigration, all Danish residents are provided a unique personal identification number that is only given once and follows the person until death. The number enables cross-linkage of the different Danish administrative registries. 16 Through the Danish Civil Registration System, it is possible to obtain information on date of birth, gender, date of death, and vital status. 17 Through the Danish National Prescription
Register it is possible to obtain information on all claimed prescriptions from all Danish pharmacies, and through this registry information on strength dosage and number of tablets is also available. 18 All prescription drugs are classified according to the Anatomical Therapeutic Chemical (ATC) classification system. 18 The Danish National Patient Register holds information on all hospital contacts (inpatient or outpatient) since 1978, registered as diagnosis codes according to the International Classification of Diseases (ICD-10). 19 Data from the general practitioners are not available through the registries. All surgical procedures are recorded according to the Nordic Classification of Surgical Procedures. 19 
Study population
Patients with an inpatient or outpatient diagnosis of deep venous thromboembolism (DVT) or pulmonary embolism (PE) between 1 January 2015 and 30 June 2017, were identified (Supplementary material online, Table S1 ). Patients were included if they had redeemed a prescription for apixaban or rivaroxaban within 7 days following a VTE diagnosis from an outpatient clinic or discharge with the diagnosis from a hospital. This definition has been used in previous studies. 1, 20 Patients under the age of 15 or over the age of 100, patients with atrial fibrillation, patients with mechanical heart valves, or patients treated with VKA, edoxaban, or dabigatran were excluded. To allow patients to collect a prescription from a pharmacy, study start was defined as 7 days after the date of diagnosis from an outpatient clinic or date of discharge. Patients were followed for 6 months or until they experienced an outcome, died, emigrated, or until study end, which ever came first.
Comorbidities
Comorbidities were identified using ICD-10 diagnosis codes registered up to 10 years prior to a diagnosis with VTE; for previous VTE, previous bleeding, stroke, acute myocardial infarction, ischaemic 
Pharmacotherapy
Baseline pharmacotherapy of included patients was identified through the Danish National Prescription Registry and included: ADP-inhibitors, aspirin, diuretics, beta-blockers, calcium channel blockers, renin-angiotensin inhibitors, loop diuretics, ulcer medication, statins, hormone replacement therapy, oral contraceptives, and non-steroidal anti-inflammatory drugs (NSAID). Patients were defined as users if they had filled a prescription within 180 days prior to the date of VTE (Supplementary material online, Table S2 ).
Outcome measures
We investigated the risk of all-cause mortality, recurrent VTE, and hospitalized bleeding. Recurrent VTE was defined as an in-hospital admission, using only primary inpatients hospital admissions. Hospitalized bleeding was defined as an inpatient hospital admission with a bleeding diagnosis. Secondary safety outcomes included intracranial and gastrointestinal bleeding. The positive predictive value of the bleeding diagnosis in the registries has been found to be in the range of 89-99%. 21 This means that among those patients diagnosed with a hospitalized bleeding, 89-99% had a true bleeding.
Statistical analyses
To investigate differences in baseline characteristics between patients treated with either rivaroxaban or apixaban, the v 2 test was used for categorical variables and the Wilcoxon rank test was used for continuous variables. Outcome-specific Cox regression analyses for the hazards of each of the outcomes (recurrent VTE, bleeding, intracranial bleeding, gastrointestinal bleeding, and all-cause mortality) were adjusted for potential confounders; sex, age groups (<50, 51-65, 66-75, 76-85, 86-100), calendar year, inclusion event, previous VTE, previous bleeding, hypertension, cancer, and ischaemic heart disease. None of the outcomes were considered competing risks for each other except for all-cause mortality. 20, 22 Based on the adjusted outcome-specific Cox regression models, standardized absolute risks were estimated at 3 and 6 months separately for all of the outcomes. 23, 24 Reported were outcome-specific hazard ratios and also average treatment effects as standardized differences in absolute risks between apixaban and rivaroxaban. 22, 24 Confidence intervals for the standardized absolute risk and average treatment effects were obtained based on 1000 bootstrap samples. The level of statistical significance was set at 5%. Handling of data and statistical analysis was performed using SAS (Statistical Analytical System, version 9.4, SAS Institute, Gary, NC, USA) and R. 25 
Sensitivity analyses
Four sensitivity analyses were conducted: (i) only patients with an inpatient hospital admission at index were included, (ii) excluding all patients with previous VTE, (iii) All analyses restricted to the years of 2015 and 2016, and (iv) performing subgroup analyses on patients with and without use of proton pump inhibitors, or use of antiplatelets.
Ethics
Retrospective 
Results
In total, 12 130 patients were identified with VTE, of which 3943 patients were excluded based on the defined exclusion criteria (see Methods section and Figure 1) . The final study cohort comprised 8187 patients, with 1504 (18%) patients treated with apixaban and 6683 (82%) patients treated with rivaroxaban. Patients in the apixaban group had a higher median age [70 years; interquartile range (IQR) 56-80] than patients in the rivaroxaban group (67 years; IQR 53-76) ( Table 1) . Significantly more patients in the apixaban group (54.3%) had PE as index event as opposed to rivaroxaban (38.4%) (Pvalue <0.001). Patients in the apixaban group had significantly more comorbidity such as: previous bleeding, previous stroke, previous acute myocardial infarction, ischaemic heart disease, vascular disease, chronic kidney disease, hypertension, cancer, and COPD. In addition, patients in the apixaban group used more concomitant medication, including aspirin, antihypertensive medications, and peptic ulcer medication. The patients were followed for a median time of 180 days (IQR 130-180).
All-cause mortality
The standardized absolute risk of all-cause mortality within 180 days was 5.08% (95% CI 4.08% to 6.08%) in the apixaban group and 4.60% (95% CI 4.13% to 5.18%) in the rivaroxaban group [absolute risk difference -0.48% (95% CI -1.49% to 0.72%)] Table 2 , Figures 2 and 3) . Showing no significant difference in the risk of all-cause mortality between the groups.
Recurrent venous thromboembolism
The standardized absolute 180 days risk of recurrent VTE was 2.16% (95% CI 1.49% to 2.88%) in the apixaban group and 2.22% (95% CI 1.89% to 2.52%) in the rivaroxaban group [absolute risk difference of 0.06% (95% CI -0.72% to 0.79%)] Table 2 , Figures 2 and 3) . Showing no significant difference in the risk of recurrent VTE between the groups.
Bleeding
The standardized 180 days risk of hospitalized bleeding was 1.73% (95% CI 1.22% to 2.35%) for patients in the apixaban group and 1.89% (95% CI 1.56% to 2.20%) in the rivaroxaban group [absolute risk difference of 0.16% (95% CI -0.59% to 0.81%)] ( Table 2 , Figures 2 and 3) . Showing no significant difference in the risk of hospitalized bleeding between the groups. Nor was there found any significant difference in the absolute risks with regard to gastrointestinal [absolute risk difference of -0.08% (95% CI -0.70% to 0.43%)] and intracranial bleeding [absolute risk difference of 0.00% (95% CI -0.25% to 0.21%)].
Subgroup and sensitivity analyses
Similar associations were found for all of the outcomes in all sensitivity analyses, where only inpatient diagnoses were used as inclusion event, where all patients had at least 6 months follow-up, when patients with prior VTE were excluded, and when performing 
Discussion
In this study, including 8187 patients with VTE treated with either rivaroxaban or apixaban, there were no significant differences between patients treated with rivaroxaban or apixaban in the risk of allcause mortality, recurrent VTE, or hospitalized bleeding. Importantly, our study provides information on the comparative safety and effectiveness of rivaroxaban and apixaban when compared directly. Until now, the lack of direct comparison between apixaban and rivaroxaban has made it difficult to choose an agent based on the relative risk-benefit profile. In the absence of head-to-head clinical trials, available evidence regarding the risk-benefit profile has been obtained through meta-analyses comparing the EINSTEIN and AMPLIFY studies. 12, 13 However, these studies differed with regard to study design and inclusion and exclusion criteria. [7] [8] [9] It is therefore important to keep these differences in study design in mind when comparing the thrombo-embolic and bleeding rates between the trials. 14 There are several differences between our population and the study populations included in the randomized trials. The patient population included in our study had a higher median age that were 10 years above the mean age of 57 reported in the AMPLIFY and EINSTEIN studies. [7] [8] [9] This may have influenced the proportion of patients with other comorbidities (such as hypertension, COPD, previous bleeding, and ischaemic heart disease) than reported in the three randomized trials. Noteworthy, a higher proportion of patients with previous VTE were included in the trials, compared with our study, which may have influenced the risk of recurrent VTE. Another difference was the number of patients with active cancer that were reported in the range between 2.5% in the AMPLIFY study to 6.8% in the EINSTEIN-DVT study. The proportion of patients with cancer was higher in our study and ranged from 14.0% in the apixaban group to 11.4% in the rivaroxaban group. The higher proportion of patients with cancer in our study might be explained by the fact that we were not able to differentiate between active or recent cancer and that our population was older. Another major difference was the proportion of patients with thrombophilia that were higher in the randomized trials compared with our study. This may reflect differences in screening programs between countries.
We found a standardized risk of all-cause mortality of 5.1% for patients in the apixaban group and 4.6% for patients in the rivaroxaban group, showing no significant difference in the risk of all-cause mortality between the groups. The higher rate of mortality in the apixaban group can be explained by the apixaban group being older, and by the higher proportion of patients with PE. It is well known that age increases the risk of mortality, but it has also been shown that the risk of death is 18-fold higher in patients experiencing a PE compared with a DVT. 26 In comparison, the reported mortality rates were 0.3-2.4% in the EINSTEN studies and 1.5% in the AMPLIFY study. 8, 9 Allcause mortality can be used as a measure of how the general health is of the investigated patient population. 14 The finding that all-cause mortality was higher in our study (standardized absolute risk: apixaban 5.1% and rivaroxaban 4.6%) is not surprising considering the strict inclusion and exclusion criteria used in randomized clinical trials, making the generalizability to real-world populations difficult. The absolute rate of recurrent VTE was 2.1% in the EINSTEIN studies and 2.3% in the AMPLIFY study, meta-analyses have found this difference to be insignificant 12, 13 Our results compare well with the absolute risks of recurrent VTE observed in the two trials, with 2.2% and 2.2% experienced a recurrent event in the apixaban and rivaroxaban groups, respectively. In addition, our results regarding an insignificant difference in the risk of recurrent VTE also compares well with the results found in meta-analyses. 12, 13 The absolute rate of bleeding was 1.0-1.7% in the EINSTEIN studies and 0.6% in the AMPLIFY study. [7] [8] [9] Meta-analyses have found that there was no significant difference in the risk of bleeding between the two groups. 12, 13 In contrast, Cohen et al.
12
found that apixaban was associated with a significantly lower risk of clinically relevant non-major bleeding or major bleeding [HR 0.47 (95% CI 0.36% to 0.61%)]. We did not find a significant difference in the risk of hospitalized bleeding, which may be explained by our bleeding definition. We defined a bleeding as a bleeding that led to an inpatient hospital admission; this may have underestimated the rate of bleeding, as clinically relevant minor bleedings cannot be identified. There are several strengths in this study; first we were able to describe the comparative safety and effectiveness of rivaroxaban and apixaban in patients seen in the everyday practice. Figure 3 Adjusted hazard ratios. Adjusted hazard ratios for the relative risks of all-cause mortality, recurrent venous thromboembolism (VTE), and hospitalized bleeding. Apixaban was used as the reference. The models were adjusted for: Sex, age groups (<50, 51-65, 66-75, 76-85, 86-100), calendar year, inclusion event, previous venous thromboembolism, previous bleeding, hypertension, cancer, and ischaemic heart disease. CI, confidence interval.
Safety and effectiveness of rivaroxaban and apixaban Second, patients were included regardless of socio-demographic or economic status. However, there were also limitations to this study; our study was limited by the size of the population, which might have led the study to be underpowered to detect a difference between the two groups. Another major limitation was the major differences observed between the rivaroxaban and apixaban group. Patients in the apixaban group were older and more comorbid than the patients in the rivaroxaban group, thus it may be that patients in the apixaban group also had a higher risk of bleeding. In addition, significantly more patients in the apixaban group had PE as index event. This can possibly be explained by PE being a condition that affects more elderly patients, thus because patients in the apixaban group were older than the patients in the rivaroxaban group, this can explain the difference. However, we adjusted for these major differences in age and comorbidities, and thus, within the limitations of correct specifications of our models, these differences should not bias our results. Another limitation is the potential for residual confounding as potential confounders were not available in the registries. These include: body mass index, smoking status, and important clinical parameters such as: eGFR, hepatic status, blood pressure, and lipid status This argues for a head-to-head randomized trial, which could provide more causal results. Such study has been scheduled and will be of high relevance to the both the medical field and patients. Another limitation was the lack of adjudication of the events. We only used inpatient hospital admissions and primary diagnosis as outcome events; however, it is possible that we have underestimated the number of recurrent VTEs and bleedings in both groups by using this definition.
Conclusion
We found no significant differences in a nationwide cohort of VTE patients treated with rivaroxaban or apixaban regarding the shortterm risks of all-cause mortality, recurrent VTE, or hospitalized bleeding. Our study compared rivaroxaban and apixaban, using an observational study design, and gives an insight into the absolute risks of recurrent VTE and bleeding when rivaroxaban and apixaban are used in the everyday clinical practice.
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